Abbott Wins FDA Approval for Aveir VR Mini, Its Smallest Leadless Pacemaker Yet

Abbott (NYSE: ABT) announced on September 15, 2026 that the U.S. Food and Drug Administration approved its Aveir VR Mini ventricular leadless pacemaker, a 32.5 mm device that is 14 percent shorter than the existing 38.0 mm Aveir VR. The approval marks the latest step in the company's effort to shrink leadless pacing technology while preserving the longevity and dual-chamber capabilities that have defined its Aveir platform. The device is the smallest ventricular leadless pacemaker Abbott has brought to market, and it arrives alongside the Aveir AR2 atrial leadless pacemaker as part of a next-generation pairing for the Aveir DR leadless pacing system.

Leadless pacemakers differ fundamentally from traditional pacemakers. Instead of relying on cardiac leads threaded through veins to the heart, these devices are implanted directly into the heart muscle through a minimally invasive catheter-based procedure. That approach eliminates the need for leads, leaves no chest scar, and keeps the device invisible to the eye. For patients who need pacing to treat slow heart rhythms, the technology has offered a way to avoid some of the long-term complications associated with lead-based systems.

Abbott has been a central player in the leadless category. The company's Aveir DR system is described by Abbott as the world's only dual-chamber leadless pacemaker system, and it is powered by the company's implant-to-implant, or i2i, in-body communication technology. That technology enables beat-to-beat communication between two leadless pacemakers, one in the atrium and one in the ventricle, so the heart's chambers can be activated synchronously. The first version of Aveir DR was implanted in clinical trials in 2022, with FDA approval coming the following year, according to MassDevice and Voice of Healthcare. MD+DI dates that dual-chamber approval to 2024.

The new approval also highlights the competitive dynamics in leadless pacing. Medtronic, a major rival in cardiac rhythm management, markets the Micra leadless pacemaker, which is 25.9 mm long. Abbott's Aveir VR Mini at 32.5 mm remains longer than Micra, but Abbott is betting that its dual-chamber architecture and ventricular longevity give it a different kind of advantage. The company's pitch is not simply about size; it is about expanding the range of patients who can receive leadless pacing.

Key Facts

MassDevice reported on September 15, 2026 that Abbott said the FDA approved the Aveir VR Mini ventricular leadless pacemaker, the smallest version yet of its Aveir leadless pacemaker family. The device measures 32.5 mm, a 14 percent reduction from the 38.0 mm existing Aveir VR ventricular leadless pacemaker. Abbott said it designed the system to deliver longevity in a smaller form factor. For comparison, Medtronic's competing Micra leadless pacemaker is 25.9 mm long. The article was written by MassDevice executive editor Chris Newmarker.

MD+DI reported on September 15, 2026 that the shorter length of the Aveir VR Mini expands implant options within the right ventricle and provides more implant options for treating patients with slow heart rhythms. The outlet noted that Abbott had earlier scored FDA approval for the Aveir DR dual-chamber leadless pacemaker, which MD+DI dates to 2024. That dual-chamber capability sets Abbott apart from Medtronic, which relies on a single-unit approach in leadless pacing with its Micra platform, according to MD+DI. The report was written by senior editor Amanda Pedersen.

Cardiovascular Business reported on September 15, 2026 that the FDA approved the Aveir VR Mini, which is 14 percent shorter than the prior Aveir VR, shortened from 38 mm to 32.5 mm. According to Abbott, the device offers an additional option to patients who require a lower-profile device, potentially expanding the number of patients who can be treated with a leadless pacing system, and it expands implant options in the smaller space of the right ventricle.

Voice of Healthcare reported on September 16, 2026 that Abbott won FDA approval for the Aveir VR Mini. The outlet confirmed the 32.5 mm length and the 14 percent reduction from the 38.0 mm Aveir VR. It also noted that Abbott designed the system to deliver longevity in a smaller form factor and repeated the comparison to Medtronic's 25.9 mm Micra. Voice of Healthcare described the Aveir AR2 and Aveir VR Mini as representing the next generation of the Aveir DR LP system.

Randel Woodgrift, senior vice president of Abbott's cardiac rhythm management business, said in statements carried by MassDevice and Cardiovascular Business that Abbott is advancing leadless pacing and expanding options for physicians and patients. He added that the Aveir AR2 and Aveir VR Mini represent the next generation of the world's only dual-chamber leadless pacing system, giving physicians a highly optimized atrial and ventricular pairing that expands the reach of the technology to a broader patient population.

Analysis

The bigger picture here is that Abbott is competing on a two-front strategy: miniaturization and system-level capability. The Aveir VR Mini's 32.5 mm length is a meaningful engineering achievement, but it does not make Abbott the smallest device in the category. Medtronic's Micra remains shorter at 25.9 mm. What Abbott is arguing, through the pairing of the Aveir AR2 atrial device and the Aveir VR Mini ventricular device, is that the future of leadless pacing is not about a single tiny device but about a coordinated dual-chamber system.

That distinction matters because leadless pacing was previously limited to patients who only needed single-ventricle pacing, according to Cardiovascular Business. Many patients need biventricular pacing, and dual-chamber leadless systems have helped expand care to a larger percentage of patients. By shrinking the ventricular device while keeping the dual-chamber architecture, Abbott is trying to serve patients who might benefit from a lower-profile implant without giving up synchronous activation. The i2i communication technology is the glue that holds that promise together.

The regulatory timeline also tells a story. MassDevice and Voice of Healthcare report that the first Aveir DR was implanted in clinical trials in 2022, with FDA approval coming the following year. MD+DI dates the Aveir DR approval to 2024. Whatever the exact date, the arc is clear: Abbott has moved from first-in-human trials to a dual-chamber approval to a second-generation, smaller ventricular device in a relatively short period. That cadence suggests the company is iterating quickly on a platform it believes can become a standard of care.

Competitively, Medtronic's single-unit Micra approach has its own advantages, including a very small footprint. But Abbott's dual-chamber system is a differentiator that Medtronic does not currently match in leadless pacing, according to MD+DI. The question is whether physicians will prioritize the smallest possible ventricular device or the ability to pace both chambers without leads. Abbott is betting on the latter, and the Aveir VR Mini is designed to make that bet more palatable by reducing the size penalty.

Why It Matters

For patients with slow heart rhythms, the approval expands the menu of leadless options. A shorter ventricular device can be easier to place within the right ventricle, which is a confined space. That could make leadless pacing available to more patients who are not ideal candidates for a larger device. It also offers an alternative for patients who want to avoid the chest scar and visible hardware associated with traditional pacemakers.

The approval also matters for the broader direction of cardiac rhythm management. Leadless pacing has moved from a niche option for single-chamber pacing to a platform that can address dual-chamber needs. Abbott's emphasis on longevity in a smaller form factor speaks to a key concern: patients and physicians want devices that last, and they do not want to trade durability for size. If the Aveir VR Mini delivers on that promise, it could accelerate the shift away from lead-based systems.

Finally, the competitive pressure is likely to benefit patients. Medtronic's Micra at 25.9 mm sets a size benchmark, while Abbott's dual-chamber capability sets a functional benchmark. The race between these two approaches could drive further innovation in device miniaturization, battery longevity, and communication between implants. That is a dynamic worth watching.

Next Up

Abbott will now focus on commercial launch and clinician training for the Aveir VR Mini and the Aveir AR2. The company has not disclosed pricing or a specific rollout schedule in the materials reviewed here. Physicians and hospital systems will be looking for real-world data on implant success, device longevity, and the performance of the i2i communication link in everyday practice.

Longer term, the key question is whether dual-chamber leadless pacing becomes the default for appropriate patients, or remains a specialized option. Abbott's next moves, and Medtronic's response, will shape that answer. For now, the FDA approval of the Aveir VR Mini gives Abbott a smaller building block for a system it already markets as unique.